Amylyx Pharmaceuticals (AMLX) vs Legend Biotech (LEGN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Amylyx Pharmaceuticals (AMLX) has outperformed Legend Biotech (LEGN) over the past year, gaining 101.8% versus a loss of 41.9%. Legend Biotech is the larger company by market cap ($3.67 billion vs $3.56 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AMLX | LEGN |
|---|---|---|
| Share price | $28.37 | $18.85 |
| Market cap | $3.56B | $3.67B |
| 1-day change | +4.29% | +0.75% |
| YTD return | +125.17% | -13.94% |
| 1-year return | +101.78% | -41.91% |
| 5-year return | — | -63.96% |
| Forward P/E | — | 17.95 |
| EPS (TTM) | $-1.41 | $-0.52 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $0 | $1.03B |
| Revenue growth (YoY) | -100.00% | +64.04% |
| Net income (latest FY) | $-144.74M | $-296.80M |
| Gross margin | — | 61.41% |
| Operating margin | — | -13.27% |
| Net margin | — | -28.85% |
| 52-week high | $41.14 | $37.50 |
| 52-week low | $10.83 | $16.24 |
| Distance from 52-week high | -31.05% | -49.73% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +49.33% | +146.68% |
| Average volume | 2.35M | 2.37M |
| Shares outstanding | 125.51M | 194.49M |
| Employees | 136 | 3,200 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- AMLX has outperformed LEGN by 143.7 percentage points over the past year.
- Legend Biotech grew revenue faster in its latest fiscal year (+64.04% vs -100.00%).
About Amylyx Pharmaceuticals
AMLX stock →Amylyx Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for neurodegenerative diseases and endocrine conditions in the United States. It provides Avexitide, an investigational, first-in-class glucagon-like peptide-1, or GLP-1 receptor antagonist, which is in phase 3 clinical trial to treat post-bariatric hypoglycemia and congenital hyperinsulinism.
Health Care · Biotechnology: Pharmaceutical Preparations · 136 employees
About Legend Biotech
LEGN stock →Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe. Its lead product candidate is ciltacabtagene autoleucel, or cilta-cel, which is a chimeric antigen receptor (CAR-T) therapy for the treatment of multiple myeloma (MM).
Health Care · Biotechnology: Pharmaceutical Preparations · 3,200 employees
AMLX vs LEGN FAQ
Which is bigger, Amylyx Pharmaceuticals or Legend Biotech?
Legend Biotech (LEGN) is larger, with a market capitalization of $3.67B compared with $3.56B for Amylyx Pharmaceuticals (AMLX).
Which stock has performed better over the past year, AMLX or LEGN?
AMLX returned +101.78% over the past 12 months, compared with -41.91% for LEGN (price return, excluding dividends). Past performance does not predict future results.
Are Amylyx Pharmaceuticals and Legend Biotech in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.